Skip to content

A clinical study of traditional Chinese medicine prolonging the survival of advanced gastric cancer patients by regulating the immunosuppressive cell population: A study protocol for a multicenter, randomized controlled trail

A clinical study of Traditional Chinese Medicine prolonging the survival of advanced gastric cancer patients by regulating the immunosuppressive cell population

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900028147
Enrollment
Unknown
Registered
2019-12-13
Start date
2020-02-01
Completion date
Unknown
Last updated
2020-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer

Interventions

Sponsors

Jiangsu Province Hospital of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients with pathological diagnosis of gastric cancer; 2. Patients with histologically or cytologically confirmed stage III after resection or IV,who cannot undergo radical surgery or postoperative recurrence and metastasis; 3. KPS scores >60; 4. Aged from 18 to 75 years old; 5. Patients with life expectancy of at least 6 months; 6. Patients who provide written informed conset to participate in the study according to the GCP criteria; 7. Childbearing age women whose urine pregnancy test is negative within 7 days before enrollment. All the patients and their spouse should abstinence all the time or at fixed periods during this trail or take at least 2 effective contraceptives. Abstinence or contraceptives still need to be used for 2 years after the trail.

Exclusion criteria

Exclusion criteria: 1. Patients who is unable to swallow oral medications(including with digestive tract obstruction and jejunostomy; 2. Patients with symptomatic brain metastasis or mental disorder; 3. Patients who has severe cardiovascular disease, hepatopathy, kidney disease or blood disease; 4. Patients whose laboratory examination before enrollment is abnormal: Blood routine examination: ANC1.5 UNL, CCr1.5 UNL, ALT(SGPT) and AST(SGOT) >1.5×UNL; 5. Patients who are pregnant, nursing; 6. Patients who are substance abuse,or with clinical ,mental and social features which is interference for the study and informed consent.

Design outcomes

Primary

MeasureTime frame
1 year survival rate;progression free survival;

Secondary

MeasureTime frame
overall survival;objective remission rate;tumor marker;TCM sydrome score;piper fatigue scale;immunosuppressive cell population;cytokines;Quality of life;

Countries

China

Contacts

Public ContactXi Zou

Jiangsu Province Hospital of Chinese Medicine

zxvery@126.com+86 18051983568

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 18, 2026